Infinimmune | News

News & Media

All

Press Releases

News Articles

Publications

Alameda biotech Infinimmune scores $75 million as it plans first clinical trials

August 11, 2026

Chasing Dupixent, a biotech aims to make better antibody drugs for eczema

August 11, 2026

Epicrispr, Infinimmune snag combined $165M in VC cash

August 11, 2026

Infinimmune bags $75M for atopic dermatitis antibody duo

August 11, 2026

Infinimmune Raises $75 Million Series A Financing to Advance Pipeline of Human-Derived Antibodies for Atopic Dermatitis and Inflammatory Disease

August 11, 2026

Infinimmune Secures $75M for a More Human Approach to Developing Better Antibody Drugs

August 11, 2026

Lilly paid $2B upfront for vaccine biotechs; Infinimmune raises $75M

August 11, 2026

Re-engineering immune memory for tissue repair

August 11, 2026

Regeneron backs $75M Series A for antibody upstart Infinimmune

August 11, 2026

Infinimune's Dr McDonnell on How Converging Human-Based Technologies Are Defining the Next Era of Clinical Development

Beyond Engineered Antibodies: Harnessing The Natural Human Repertoire

Building A New Antibody Discovery Platform With Infinimmune's Wyatt McDonnell, Ph.D.

Merck bets on antibody startup Infinimmune for longevity edge

Infinimmune Enters Collaboration with Merck to Discover Novel Human Antibody Therapeutics

Infinimmune, Merck enter into antibody discovery pact

Merck enlists antibody hunter Infinimmune for $838M biobucks pact

Merck joins forces with small startup to find therapeutic antibodies

Merck strikes deal with antibody discovery startup

KBI Biopharma, Inc. Announces Collaboration with Infinimmune Inc. to Support Antibody Manufacturing

September 8, 2025

KBI Biopharma, Infinimmune Partner to Support Antibody Manufacturing

September 8, 2025

AI News: Alameda based Infinimmune launched its GLIMPSE-1 antibody engineering platform that is based on a protein language model focused on native human antibody sequences

Better Antibodies Engineered with GLIMPSE of Human Data

How Infinimmune is Transforming Therapeutic Antibody Engineering

Infinimmune Launches GLIMPSE-1 AI Model Trained Exclusively on Human Antibody Sequences for Advanced Therapeutic Engineering

Infinimmune’s AI Model GLIMPSE-1 Engineers Human-Sourced Antibodies

Insight on FDA’s Plan to Phase Out Animal Testing for mAbs and Other Drugs

FDA wants a shift away from animal testing

FDA wants to get rid of animal testing requirements for antibody drugs

Infinimmune Appoints Dr. Tim Sullivan as Chief Business Officer

September 3, 2024

Infinimmune Appoints Dr. Neela Patel to Board of Directors

Infinimmune, Grid Therapeutics Strike Antibody-Based Cancer Drug Discovery Partnership

January 5, 2024

Infinimmune Announces Partnership with Grid Therapeutics to Conduct Deep Sequencing of B Cells for Oncology Drug Discovery

December 19, 2023

Bio’s Next Tool Builders

Spotlight on Infinimmune

Founding Infinimmune and Developing Breakthrough Tools for Antibody Discovery

$12-Million Seed Funding to Design Drugs Using Human-Sourced Antibodies

December 6, 2022

Infinimmune’s secret for building better antibody drugs: You

December 6, 2022

Infinimmune Raises $75 Million Series A to Advance Human-Derived Antibody Pipeline for Atopic Dermatitis

Infinimmune raises USD 75m to bring IL-22 antibody into clinic

Inside the AD Pipeline: Infinimmune Raises $75 Million Series A to Advance Its AD Candidates